PMID- 36793734
OWN - NLM
STAT- MEDLINE
DCOM- 20230217
LR  - 20230217
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Association between human leukocyte antigen and immunosuppressive treatment 
      outcomes in Chinese patients with aplastic anemia.
PG  - 1056381
LID - 10.3389/fimmu.2023.1056381 [doi]
LID - 1056381
AB  - BACKGROUND: Activated cytotoxic T cells (CTLs) recognize the auto-antigens 
      presented on hematopoietic stem/progenitor cells (HSPCs) through class I human 
      leukocyte antigen (HLA) molecules and play an important role in the immune 
      pathogenesis of aplastic anemia (AA). Previous reports demonstrated that HLA was 
      related to the disease susceptibility and response to immunosuppressive therapy 
      (IST) in AA patients. Recent studies have indicated that specific HLA allele 
      deletions, which helped AA patients to evade CTL-driven autoimmune responses and 
      escape from immune surveillance, may lead to high-risk clonal evolution. 
      Therefore, HLA genotyping has a particular predictive value for the response to 
      IST and the risk of clonal evolution. However, there are limited studies on this 
      topic in the Chinese population. METHODS: To explore the value of HLA genotyping 
      in Chinese patients with AA, 95 AA patients treated with IST were retrospectively 
      investigated. RESULTS: The alleles HLA-B*15:18 and HLA-C*04:01 were associated 
      with a superior long-term response to IST (P = 0.025; P = 0.027, respectively), 
      while the allele HLA-B*40:01 indicated an inferior result (P = 0.02). The allele 
      HLA-A*01:01 and HLA-B*54:01 were associated with high-risk clonal evolution (P = 
      0.032; P = 0.01, respectively), and the former had a higher frequency in very 
      severe AA (VSAA) patients than that in severe AA (SAA) patients (12.7% vs 0%, P = 
      0.02). The HLA-DQ*03:03 and HLA-DR*09:01 alleles were associated with high-risk 
      clonal evolution and poor long-term survival in patients aged >/=40 years. Such 
      patients may be recommended for early allogeneic hematopoietic stem cell 
      transplantation rather than the routine IST treatment. CONCLUSION: HLA genotype 
      has crucial value in predicting the outcome of IST and long-term survival in AA 
      patients, and thus may assist an individualized treatment strategy.
CI  - Copyright (c) 2023 Chen, Ge, Huo, Ren, Shao, Li, Huang, Wang, Nie, Zhang, Peng and 
      Zheng.
FAU - Chen, Lingyun
AU  - Chen L
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Ge, Meili
AU  - Ge M
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Huo, Jiali
AU  - Huo J
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Ren, Xiang
AU  - Ren X
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Shao, Yingqi
AU  - Shao Y
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Li, Xingxin
AU  - Li X
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Huang, Jinbo
AU  - Huang J
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Wang, Min
AU  - Wang M
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Nie, Neng
AU  - Nie N
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Peng, Jin
AU  - Peng J
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
FAU - Zheng, Yizhou
AU  - Zheng Y
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of 
      Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & 
      Peking Union Medical College, Tianjin, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230130
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-B Antigens)
SB  - IM
MH  - Humans
MH  - *Anemia, Aplastic/drug therapy/genetics
MH  - Retrospective Studies
MH  - East Asian People
MH  - Immunosuppressive Agents/therapeutic use
MH  - Treatment Outcome
MH  - HLA Antigens/genetics
MH  - HLA-B Antigens/genetics
PMC - PMC9923019
OTO - NOTNLM
OT  - HLA
OT  - aplastic anemia
OT  - clonal evolution
OT  - immunosuppressive therapy
OT  - therapy response
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/02/17 06:00
MHDA- 2023/02/18 06:00
PMCR- 2023/01/01
CRDT- 2023/02/16 02:20
PHST- 2022/09/29 00:00 [received]
PHST- 2023/01/10 00:00 [accepted]
PHST- 2023/02/16 02:20 [entrez]
PHST- 2023/02/17 06:00 [pubmed]
PHST- 2023/02/18 06:00 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1056381 [doi]
PST - epublish
SO  - Front Immunol. 2023 Jan 30;14:1056381. doi: 10.3389/fimmu.2023.1056381. 
      eCollection 2023.